How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

One expert explains why most of the time clinical trial enrollment is ‘the correct answer’ for patients. By participating in clinical trials, patients with cancer have the opportunity to find ...

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had ...

A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).

A cancer diagnosis hits like a thunderbolt, changing lives instantly and profoundly. Victor Gonzalez, senior director of patient programs and support services at The Lymphoma Research Foundation, ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Please provide your email address to receive an email when new articles are posted on . Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to ...

For most people, a cancer diagnosis—especially one such as chronic lymphocytic leukemia (CLL), a slow-growing type of blood cancer—sets off a flood of emotions. According to a 2022 Emotional Impact ...

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial Richter transformation (RT) refers to ...